









Time to death by depression status at visit within 6 months before acquired im¬
munodeficiency syndrome. CES-D indicates Center for Epidemiologie Studies
Depression Scale score.
was 18 months for the entire group. The Kaplan-Meier curves
for the depressed and nondepressed groups (Figure) were com¬
pared using the log rank procedure (P=.49). The finding from
the multivariate Cox model showed a risk hazard for those with
CES-D score of 16 or higher having a shorter time to death of
1.08 (95% confidence interval, 1.34 to 0.81). Analyses defining
depression in other ways based on CES-D score1 or based on
a visit within 6 months after AIDS showed similar results.
We conclude that there is no evidence that depression is
associated with a worse survival in HIV infection at any
disease stage. This further supports our previous findings1·2
and agrees with the finding by Burack et al4 that the asso¬
ciation between depression and decline in CD4 cell count does
not directly affect survival. It is important to replicate these
findings using standardized psychiatric diagnosis. Depres¬
sion occurs among 4% to 30% of HIV-infected persons, and
it is a serious condition that causes impaired functioning and
increased risk for suicide.1 Depression among HIV-infected
persons should be identified and treated aggressively.
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HIV-1 Shedding and Chlamydial Urethritis
To the Editor.\p=m-\DrsSchmid and Fontanarosa1 thoroughly
discussed the causes and management of nongonococcal ure-
thritis. However, they did not emphasize the link between
treatment of sexually transmitted diseases and prevention of
human immunodeficiency virus (HIV).2 We collected ejacu-
late from a 32-year-old white man with HIV-1 disease and a
CD4 cell count of 0.11\m=x\109/L who was taking no antiretroviral
therapy. The patient had chlamydial urethritis at the time the
sample was obtained, with dysuria but without discharge. We
performed quantitative HIV-1 culture on his seminal cell
fraction, using a modification of the AIDS Clinical Trials
Group quantitative cell culture protocol. We had previously
performed 32 quantitative cultures for HIV-1 using seminal
cells from 25 HIV-1\p=m-\infectedindividuals; the range of excre-
tion was <3.0 to 2523.3 infectious units per ejaculate. Our
patient excreted 6729 infectious units of HIV-1 in his ejacu-
late obtained at the time of chlamydial infection (P<.001 for
the comparison of subjects without symptoms ofurethritis vs
subjects with symptomatic urethritis). We also analyzed the
seminal plasma by reverse transcriptase polymerase chain
reaction, using a commercial assay (HIV-1 Amplicor Monitor,
Roche Biomedicai Laboratories, Research Triangle Park, NC).
The patient excreted 375000 copies of HIV-1 RNA per mil-
liliter of seminal plasma. Four weeks after the patient com¬
pleted therapy for chlamydial infection, we reexamined the
semen for HIV-1. The quantitative culture could not be done.
However, the copies of HIV-1 RNA in the seminal plasma at
this time were reduced to 7500 per milliliter. Using an al¬
ternative amplification method that uses silica beads to sepa¬
rate HIV-1 RNA from potential inhibitors,3 the results from
the pretreatment and posttreatment samples were 1200 000
and 12 000 copies per milliliter, respectively. The patient re¬
ceived no antiretroviral therapy during this interval. These
results suggest chlamydial urethritis may increase shedding
of HIV-1 in semen, and treatment of chlamydial urethritis
may decrease shedding of HIV-1. Moss and coworkers4 have
reported that treatment of gonococcal urethritis in HIV-
positive men decreases detection of HIV-1 in urethral swab
specimens. These observations provide biological support to
the recent observation that aggressive therapy for sexually
transmitted diseases reduces transmission of HIV.5




Myron S. Cohen, MD
University of North Carolina at Chapel Hill
This research was supported in part by grant UO1-AI25868-09 from the
National Institutes of Health. Assay materials were provided by Roche Bio-
medical Laboratories, Research Triangle Park, NC, and Organon-Technika,
Durham, NC.
1. Schmid GP, Fontanarosa PB. Evolving strategies for management of the
nongonococcal urethritis syndrome. JAMA. 1995;274:577-579.
2. Cohen MS, Dallabetta G, Laga M, Holmes KK. A new deal in HIV prevention:
lessons from the global approach. Ann Intern Med. 1994;120:340-341.
3. van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1
RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL)
labeled probes.J Virol Methods. 1994;49:157-167.
4. Moss GB, Overbaugh J, Welch M, et al. Human immunodeficiency virus DNA in
urethral secretions in men: association with gonococcal urethritis and CD4 cell
depletion. J Infect Dis. In press.
5. Grosskurth H, Mosha F, Todd E, et al. Impact of improved treatment of sexually
transmitted diseases on HIV infection in rural Tanzania: randomized controlled trial.
Lancet. 1995;346:530-536.
Incorrect Reference Citations in Text. \p=m-\Inthe Letters entitled
"The Relationship Between Physicians' Malpractice Claims History
and Later Claims," published in the May 17, 1995, issue of The
JOURNAL (JAMA. 1995;273:1487-1489), the reference citations in the
text of the reply by Messrs Bovbjerg and Petronis were incorrect.
The first citation to reference 1 was correct; reference 2 should have
been cited after the second and third sentences of the second para-
graph; reference citations 2, 3,4, and 5 should have been citations 3,
4, 5, and 6, respectively; and reference 6 should not have been cited
in the sixth paragraph.
